menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Biocad","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BCD-100","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Shanghai Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Shanghai Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Pharmaceuticals Holding Co.,Ltd

    Menu

    Shanghai Pharmaceuticals Holding Co.,Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Pharmaceuticals Holding Co.,Ltd

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Shanghai Pharmaceuticals Holding Co.,Ltd

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BCD-100,Pemetrexed,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Biocad

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Trial of An Original Russian Drug for The Treatment of Lung Cancer Starts in China

                            Details : The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NS...

                            Brand Name : BCD-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 13, 2021

                            Lead Product(s) : BCD-100,Pemetrexed,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Biocad

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth